Literature DB >> 3018709

Hepatocellular carcinoma presenting as a solitary metastasis to the scapula. Case report and review of the literature.

J L Zeller, M L Ireland.   

Abstract

Although primary hepatocellular carcinoma is uncommon, metastasis to the upper extremity as a presenting symptom is even more rare. Recent case reports and autopsy surveys document that extrahepatic spread of this carcinoma occurs in 30% to 78% of patients, who usually are without regional symptoms involving bone. Although metastatic spread to the lungs and lymph nodes occurs more commonly, the incidence of bone metastases has increased according to previous reports and is now estimated from 2% to 13%. This case report concerns widely disseminated hepatocellular carcinoma presenting initially without any other systemic signs except for shoulder pain and induration. Due to the aggressive nature of this tumor, early detection is crucial. Early diagnosis may offer the only real hope for establishing effective treatment and improving the chances for long-term survival.

Entities:  

Mesh:

Year:  1986        PMID: 3018709     DOI: 10.3928/0147-7447-19860701-10

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  3 in total

1.  Spinal cord compression secondary to bone metastases from hepatocellular carcinoma.

Authors:  Dinesh Chandra Doval; Komal Bhatia; Ashok Kumar Vaid; Keechelat Pavithran; Jai Bhagwan Sharma; Digant Hazarika; Amarnath Jena
Journal:  World J Gastroenterol       Date:  2006-08-28       Impact factor: 5.742

2.  Osseous metastases from hepatocellular carcinoma: embolization for pain control.

Authors:  Y Nagata; Y Nakano; M Abe; M Takahashi; S Kohno
Journal:  Cardiovasc Intervent Radiol       Date:  1989 May-Jun       Impact factor: 2.740

3.  A case report of metastatic hepatocellular carcinoma in the mandible and coracoid process: A rare presentation.

Authors:  Ahmad Bakhtiar Md Radzi; Soek-Siam Tan
Journal:  Medicine (Baltimore)       Date:  2018-01       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.